November 18, 2015
Global Genes Webinar: Learning More About Informed Consent
Informed consent is intended to provide patients, clinical trial participants, and others undergoing medical procedures with the information they need to make a decision about whether to undergo a specific procedure or participate in research. The process of informed consent can sometimes be very legal in nature leading to lack of clarity and misunderstanding. This webinar will explain the informed consent process, why patients should pay attention to it, and why rare disease advocates may want to get involved in the process. Rare disease organizations play a critical role in connecting patients with researchers and the informed consent document is critically important. It outlines who will have access to research data that results from a study. Understanding the informed consent process and how to engage will help patients receive the greatest benefit.
November 17, 2015
Global Genes Webinar: Introducing Dr. Petra Kaufmann, NCATS ORDR
Please join us November 17, 2015 at 11:30 PST/2:30 EST, as we host a special webinar formally introducing you to Dr. PetraKaufmann, NCATS, Director, Office of Rare Diseases Research and Division of Clinical Innovation. The purpose of this Webinar is to provide the rare disease community with the opportunity to hear directly from Dr. Kaufmann about her new role, her plans for the Office and most importantly, how she wants to engage with the rare disease community. Questions will be taken from attendees participating in the Webinar and fielded by the Moderator, Daniel Levine, Producer of Global Genes’ RARECast podcast.
November 16, 2015
Serenus Biotherapeutics to Launch Xenex UV Disinfection Robot at IPNET-K Conference 2015 in Naivasha, Kenya
NAIVASHA, KENYA—NOVEMBER 16—Serenus Biotherapeutics, which is bridging the divide between the world’s leading healthcare markets and the growing demand for access to innovative drugs and devices in the emerging nations of Africa, today said it will launch the Xenex pulsed xenon Full-Spectrum™ ultraviolet (UV) room disinfection system at the Infection Prevention Network-Kenya, or IPNET-K Conference 2015 in Kenya.
October 27, 2015
Serenus Biotherapeutics Enters Agreement with Hanmi Pharmaceutical to Bring Combination Therapy to Treat Growing Problem of Hypertension in Africa
DUBLIN AND JOHANNESBURG—27 October 2015—Serenus Biotherapeutics, which is bridging the divide between the world’s leading healthcare markets and the growing demand for access to innovative drugs and devices in the emerging nations of Africa, today said that it has entered into an agreement with Hanmi Pharmaceutical Co. Ltd, to supply Amosartan, Hanmi’s combination therapy for the treatment of hypertension, to patients in Africa.
October 12, 2015
Serenus Biotherapeutics Opens East African Regional Office in Nairobi, Kenya
DUBLIN AND JOHANNESBURG—12 OCTOBER 2015—Serenus Biotherapeutics, which is bridging the divide between the world’s leading healthcare markets and the growing demand for access to innovative drugs and devices in the emerging nations of Africa, today announced the opening of an East African regional office in Nairobi, Kenya.
October 7, 2015
Serenus Biotherapeutics President Dr. Skhumbuzo Ngozwana to Participate in World Health Summit in Berlin
DUBLIN AND JOHANNESBURG—October 7, 2015—Serenus Biotherapeutics today announced that its President Dr. Skhumbuzo Ngozwana will participate as a panelist in the workshop “Access to Essential Medicines and Health Commodities in Africa” on 13 October 2015 at the upcoming World Health Summit in Berlin, which is jointly organized by the Joint United Nations Programme on HIV/AIDS and the German Healthcare Partnership.
September 17, 2015
Serenus Biotherapeutics Partners With Xenex to Bring Xenex Disinfection Robots to Africa
DUBLIN, IRELAND and JOHANNESBURG, SOUTH AFRICA–(Marketwired – Sep 17, 2015) – Serenus Biotherapeutics, which is bridging the divide between the world’s leading healthcare markets and the growing demand for access to innovative drugs and devices in the emerging nations of Africa, today said it had entered into an agreement with Xenex Disinfection Services to bring the Xenex pulsed xenon Full-Spectrum™ ultraviolet (UV) room disinfection system to Africa.
August 5, 2015
Optimizing Your Loved One’s Learning and Potential at School
Children with rare diseases sometimes suffer different academic obstacles and challenges while attending school. However, there are certain programs and resources available that can help, such as 504 plans and Individualized Education Plans (IEPs). But what exactly is a 504 plan or an IEP? And how do I obtain them? The main difference between the two is that a 504 plan modifies a student’s regular education program in a regular classroom setting. A 504 plan is monitored by classroom teachers. A student with an IEP, on the other hand, may receive different educational services in a special or regular educational setting, depending on the student’s need. IEP programs are delivered and monitored by additional school support staff.
July 21, 2015
MLS Capital Fund II Initiates Investment Activity With Funding of Two Transformative Biotechnology Companies
SAN FRANCISCO, CA and KUALA LUMPUR, MALAYSIA--(Marketwired - Jul 21, 2015) - MLS Capital Fund II, co-managed by Spruce Capital Partners and Xeraya Capital, announced at the 12th Annual BIO World Congress on Industrial Biotechnology that it had initiated its investment activities by serving as lead investor in funding rounds of two innovative companies harnessing biotechnology to fundamentally transform the industries they serve.
July 17, 2015
Spruce Capital Partners' Ganesh Kishore and Roger Wyse to Address 12th Annual BIO World Congress on Industrial Biotechnology
SAN FRANCISCO, CA--(Marketwired - Jul 17, 2015) - Spruce Capital Partners' Managing Partners Dr. Ganesh Kishore and Dr. Roger Wyse, industrial biotechnology thought leaders and investors, will be featured at the 12th Annual BIO World Congress on Industrial Biotechnology.
July 8, 2015
Serenus Biotherapeutics Names Renowned Industry Leader Skhumbuzo Ngozwana, M.D., as President
Dublin and Johannesburg—July 8, 2015—Serenus Biotherapeutics, Inc. today named Skhumbuzo Ngozwana, M.D., an internationally recognized pharmaceutical development expert, as President of the company.
June 24, 2015
Spruce Capital Partner's Ganesh Kishore Named to Scientific American List of Most Influential People in Biotech
SAN FRANCISCO, CA--(Marketwired - Jun 24, 2015) - Scientific American WorldVIEW named Ganesh Kishore, Managing Partner of Spruce Capital Partners and CEO of the Malaysian Life Sciences Capital Fund, to The WorldVIEW 100, a list of the most influential people in biotech today. The publication, which examines innovation in global biotechnology, was released during a Super Session at the 2015 BIO International Convention in Philadelphia June 18.
June 11, 2015
Former Elan CEO Takes Helm of Expanded Serenus Biotherapeutics Board of Directors
SAN FRANCISCO, CA and JOHANNESBURG, SOUTH AFRICA—June 11, 2015)—Serenus Biotherapeutics, Inc., a specialty biopharmaceutical company bridging the divide between the world’s leading pharmaceutical markets and the growing demand for access to innovative therapies in the emerging nations of Africa, announced G. Kelly Martin, director of Malin Corporation plc and former CEO of Elan Corporation, began serving as Chairman of Serenus Biotherapeutics today.
June 1, 2015
Global Genes Webinar: Leveraging a Rare Disease Center of Excellence
As many patient advocates continue on their journey to become empowered activists, some may learn and want to consider starting a rare disease center of excellence. A center of excellence is a facility or centralized program that brings together a multidisciplinary, coordinated team who provide best practices, family support, and research.
This webinar covers how this can be done, what the obstacles and challenges are, and whether there are other options viewers should consider (like utilizing other centers that already exist). The panelists who are participating will approach this topic from different angels, sharing what they have learned and points to consider.
April 14, 2015
In Africa, Moving From A Brain Drain To A Brain Gain
Opinion piece by Dr. Menghis Bairu, CEO of Serenus Biotherapeutics in Forbes
April 1
Global Genes Webinar: How to Discuss Genetic Disease with Your Loved Ones
There are currently about 7,000 rare diseases identified worldwide, and approximately 80 percent of these are caused by genetic changes. But genetics is a topic that not all of us are familiar with.
This webinar covers the basics of the underlying genetics of rare disease and provides viewers with the strategies and advice to discuss them with the ones they love. Panelists shared strategies they have used to explain genetic disease, challenges they faced, and helpful resources.
March 3, 2015
Serenus Biotherapeutics Enters Equity Purchase and Acquisition Agreement With Ireland-Based Global Life Sciences Company
Malin Corporation plc to Invest up to $43 Million for up to a 76 Percent Stake in Specialty Pharmaceutical Focused on Africa
January 7, 2015
Spruce Capital and Xeraya Capital Announce First Close of $150 Million Biogreentech Venture Fund
Investments Will Target Innovative Technologies Addressing Global Societal Needs in Food and Energy Security, an Aging Population, and Sustainability
January 5, 2015
Global Genes and Levine Media Group launch RARECast
New weekly podcast focuses on rare disease at the intersection of business, policy and science.
January 5, 2015
Biotech Industry Shatters Fundraising Records in 2014, Burrill Media Reports
Ongoing fight over drug pricing overshadows industry in the new year.